Arrowstreet Capital’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-56,116
| Closed | -$18.4M | – | 1829 |
|
|
2025
Q4 | $18.4M | Sell |
56,116
-6,416
| -10% | -$2.04M | 0.01% | 761 |
|
|
2025
Q3 | $17.6M | Sell |
62,532
-151,773
| -71% | -$44M | 0.01% | 769 |
|
|
2025
Q2 | $59.8M | Buy |
+214,305
| New | +$60.7M | 0.04% | 378 |
|
|
2025
Q1 | – | Sell |
-33,756
| Closed | -$8.8M | – | 1789 |
|
|
2024
Q4 | $8.8M | Buy |
+33,756
| New | +$10M | 0.01% | 860 |
|
|
2024
Q3 | – | Sell |
-37,273
| Closed | -$11.6M | – | 1725 |
|
|
2024
Q2 | $11.6M | Buy |
37,273
+33,583
| +910% | +$9.87M | 0.01% | 600 |
|
|
2024
Q1 | $1.05M | Buy |
+3,690
| New | +$1.08M | ﹤0.01% | 1309 |
|
|
2023
Q3 | – | Sell |
-457,796
| Closed | -$102M | – | 1234 |
|
|
2023
Q2 | $102M | Sell |
457,796
-225,672
| -33% | -$52.4M | 0.12% | 162 |
|
|
2023
Q1 | $165M | Sell |
683,468
-264,568
| -28% | -$64.9M | 0.21% | 122 |
|
|
2022
Q4 | $249M | Sell |
948,036
-612,439
| -39% | -$164M | 0.35% | 84 |
|
|
2022
Q3 | $352M | Buy |
1,560,475
+194,773
| +14% | +$47.2M | 0.52% | 48 |
|
|
2022
Q2 | $332M | Buy |
1,365,702
+27,732
| +2% | +$6.8M | 0.47% | 56 |
|
|
2022
Q1 | $324M | Buy |
1,337,970
+832,885
| +165% | +$191M | 0.4% | 63 |
|
|
2021
Q4 | $114M | Buy |
505,085
+161,037
| +47% | +$34M | 0.14% | 174 |
|
|
2021
Q3 | $73.2M | Sell |
344,048
-379,693
| -52% | -$87.4M | 0.09% | 236 |
|
|
2021
Q2 | $176M | Buy |
+723,741
| New | +$178M | 0.22% | 91 |
|
|
2021
Q1 | – | Sell |
-2,300
| Closed | -$529K | – | 2216 |
|
|
2020
Q4 | $529K | Buy |
+2,300
| New | +$530K | ﹤0.01% | 2002 |
|
|
2020
Q3 | – | Sell |
-7,298
| Closed | -$1.72M | – | 2308 |
|
|
2020
Q2 | $1.72M | Sell |
7,298
-71,153
| -91% | -$16.2M | ﹤0.01% | 1543 |
|
|
2020
Q1 | $15.9M | Buy |
78,451
+55,953
| +249% | +$12.2M | 0.04% | 355 |
|
|
2019
Q4 | $5.42M | Sell |
22,498
-667,339
| -97% | -$147M | 0.01% | 831 |
|
|
2019
Q3 | $133M | Sell |
689,837
-1,298,709
| -65% | -$249M | 0.31% | 85 |
|
|
2019
Q2 | $366M | Buy |
1,988,546
+581,435
| +41% | +$104M | 0.82% | 27 |
|
|
2019
Q1 | $267M | Buy |
1,407,111
+479,659
| +52% | +$91.6M | 0.63% | 31 |
|
|
2018
Q4 | $181M | Buy |
927,452
+913,652
| +6,621% | +$178M | 0.47% | 54 |
|
|
2018
Q3 | $2.86M | Buy |
13,800
+7,700
| +126% | +$1.52M | 0.01% | 628 |
|
|
2018
Q2 | $1.13M | Buy |
+6,100
| New | +$1.08M | ﹤0.01% | 779 |
|
|
2018
Q1 | – | Sell |
-97,000
| Closed | -$16.9M | – | 1106 |
|
|
2017
Q4 | $16.9M | Buy |
97,000
+92,100
| +1,880% | +$16.3M | 0.04% | 334 |
|
|
2017
Q3 | $914K | Sell |
4,900
-3,300
| -40% | -$585K | ﹤0.01% | 842 |
|
|
2017
Q2 | $1.41M | Buy |
8,200
+3,600
| +78% | +$586K | ﹤0.01% | 714 |
|
|
2017
Q1 | $755K | Buy |
+4,600
| New | +$764K | ﹤0.01% | 1024 |
|
|
2016
Q4 | – | Sell |
-6,800
| Closed | -$1.13M | – | 1614 |
|
|
2016
Q3 | $1.13M | Sell |
6,800
-223,100
| -97% | -$37.7M | ﹤0.01% | 1045 |
|
|
2016
Q2 | $35M | Buy |
+229,900
| New | +$35.7M | 0.12% | 185 |
|
|
2015
Q4 | – | Sell |
-346,418
| Closed | -$47.9M | – | 1392 |
|
|
2015
Q3 | $47.9M | Sell |
346,418
-103,182
| -23% | -$16.3M | 0.23% | 105 |
|
|
2015
Q2 | $69M | Buy |
+449,600
| New | +$72M | 0.39% | 65 |
|
|
2015
Q1 | – | Sell |
-679,235
| Closed | -$108M | – | 978 |
|
|
2014
Q4 | $108M | Sell |
679,235
-947,407
| -58% | -$148M | 0.62% | 35 |
|
|
2014
Q3 | $228M | Sell |
1,626,642
-176,122
| -10% | -$23M | 1.23% | 12 |
|
|
2014
Q2 | $213M | Buy |
1,802,764
+951,572
| +112% | +$110M | 1.1% | 19 |
|
|
2014
Q1 | $105M | Sell |
851,192
-800,168
| -48% | -$97M | 0.64% | 35 |
|
|
2013
Q4 | $189M | Buy |
1,651,360
+104,348
| +7% | +$11.9M | 1.02% | 16 |
|
|
2013
Q3 | $173M | Buy |
1,547,012
+306,651
| +25% | +$33.3M | 1.1% | 13 |
|
|
2013
Q2 | $122M | Buy |
+1,240,361
| New | +$129M | 0.91% | 21 |
|
Other funds holding AMGN
VCM
VPM
Arrowstreet Capital's AMGN Position: Q1 2026 in Review
Arrowstreet Capital sold out of Amgen (AMGN) in Q1 2026, closing a stake of 56,116 shares — an estimated $18.4M sold.
Arrowstreet Capital first reported a position in AMGN in Q2 2013 and held it in 40 quarters. The position peaked at $366M in Q2 2019. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Arrowstreet Capital reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
- Arrowstreet Capital sold 56,116 Amgen shares in Q1 2026, an estimated $18.4M.
- Arrowstreet Capital first reported a position in Amgen in Q2 2013 and held it in 40 quarters.
- Arrowstreet Capital's Amgen position peaked at $366M in Q2 2019.
- 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.